Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.30 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19239552 | 1.00 | OGA (0.37) | OGAACHEMPOGABRA1GABRR1 | |
| Hydrochloric Acid SCHEMBL17374363 | 0.98 | OGA (0.37) | OGAACHEMPOGABRA1GABRR1 | |
| Hydrochloric Acid SCHEMBL17374365 | 0.98 | OGA (0.37) | OGAACHEMPOGABRA1GABRR1 | |
| SCHEMBL18581843 | 0.82 | OGA (0.45) | OGAACHEMPOGABRA1GABRR1 | |
| SCHEMBL19245620 | 0.79 | OGA (0.35) | OGAACHESMYD3PAK1 | |
| SCHEMBL17381653 | 0.79 | OGA (0.35) | OGAACHESMYD3PAK1 | |
| SCHEMBL3765462 | 0.77 | ACHE (0.50) | OGAACHEMPOPAK1 | |
| SCHEMBL26928851 | 0.77 | OGA (0.40) | OGAACHEMPOMAP3K7TAB1 | |
| Hydrochloric Acid SCHEMBL21640168 | 0.76 | KHK (0.37) | OGAACHEMPOPAK1 | |
| SCHEMBL17500142 | 0.75 | SMYD3 (0.36) | OGAACHESMYD3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCC2, ABCB4 | OGA 3084/4885ACHE 3811/4885MPO 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.